Opinion|Videos|May 7, 2025
Adjunctive Treatments and Apomorphine for Treatment of Parkinson Disease
Panelists discuss how adjunctive therapies play a crucial role in managing Parkinson disease symptoms, with a particular focus on apomorphine’s unique position in the treatment landscape due to its distinct dopamine receptor binding profile compared with other dopaminergic agents.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Adjunctive Therapy and Apomorphine’s Role
Role of Adjunctive Therapy:
- Extends levodopa efficacy by addressing pharmacokinetic/pharmacodynamic limitations
- Allows for levodopa dose reduction while maintaining symptom control
- Targets specific symptom patterns (eg, morning akinesia, wearing off)
- Addresses treatment gaps not fully managed by levodopa
Apomorphine’s Position in Treatment Landscape:
- Potent, nonergoline dopamine agonist
- Rapid-onset rescue medication for acute off episodes
- Continuous infusion option for patients with frequent off periods
- Bypass gastrointestinal absorption issues via subcutaneous administration
- Often considered before surgical interventions such as deep brain stimulation
Dopamine Receptor Binding Profile:
- High affinity for D2 receptors (similar to other dopamine agonists)
- Additional significant D1 receptor activity (more similar to levodopa)
- Some D3 and D4 receptor activity
- More balanced receptor profile than most oral dopamine agonists
- Rapid onset of action (10-20 minutes) compared with oral medications
Advertisement
Related to this article
Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.
Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.
The clinical professor of neurology and pediatrics at The Ohio State University Wexner Medical Center discussed payer step therapy, earlier preventive treatment, and questions the updated guideline leaves open.
Brian Snelling, MD, director of the stroke program at Marcus Neuroscience Institute discussed delays in calling 911 after stroke onset, gaps in awareness of atypical symptoms, and how to reach underserved populations.
Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.
Mitzi Joi Williams, MD, is joined by Temitope Adeola, MD, and Chantale Branson, MD, to discuss migraine as a complex neurological condition, including recognizing symptoms and triggers, navigating acute and preventive treatment options, and incorporating lifestyle modifications to improve migraine management.
The Editor-in-Chief of the Journal of the American Heart Association discussed what journal editors look for in stroke research submissions, how AI and open access are reshaping publishing, and the equity gaps that still exist for researchers in lower-income countries.
Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, discusses the Neuromuscular Advocacy Collaborative, its growing year-round presence, and what the group hopes to accomplish heading into the 2027 MDA Clinical and Scientific Conference.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Machine Learning Spots Early Signs of MS and NMOSD Years in Advance
2
Incorporating the Updated AAN/AHS Migraine Prevention Guideline Into Practice
3
Blood-Based Biomarkers for Monitoring Treatment Response in Multiple Sclerosis
4
World Stroke Day 2026: Closing the Gap Between Stroke Onset and the Emergency Call Number
5